Product

Vitamin B12 Sopharma

2 forms: solution. In force in Georgia: 2 of 2 (human register).

Forms and doses2 of 2 in force in Georgia

Form	Dose	Frequency	Georgia
500 mcg/ml, Solution	No label dose in the reference yet	-	Georgia Yes, human In force until 19 Dec 2030 Human (Ministry of Health, RAMA) In the register: ვიტამინი B12 სოფარმა 500 მკგ/მლ, 1 მლ ამპულა, საინექციო ხსნარი № რ-044521 mis.ge (Ministry of Health register incl. past registrations) Verified on: 16 Oct 2026
Details: pack, label wording, sources, registration Vitamin B12 Sopharma 500 mcg/ml, Solution 1 ml ampoule, solution for injection, human medicine vetman assessment vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient. Dog SC or IM cyanocobalamin replacement for documented or strongly supported cobalamin deficiency when parenteral treatment is clinically preferred; not nonspecific appetite support, a tonic or automatic treatment of every gastrointestinal disorder 7.4/10 Good vetman assessment Vitamin B12 Sopharma 500 mcg/ml, 1 ml ampoule, solution for injection, human medicine Assessed clinical scopeDog · SC or IM cyanocobalamin replacement for documented or strongly supported cobalamin deficiency when parenteral treatment is clinically preferred; not nonspecific appetite support, a tonic or automatic treatment of every gastrointestinal disorder · SC,IM Care settingVeterinary clinic or a trained home-treatment plan after deficiency and cause assessment, with exact small-volume measurement, injection-site rotation, follow-up cobalamin or methylmalonic-acid testing and treatment of the underlying disease vetman score 7.4/10 Good Evidence confidence: Medium Georgia: Yes, human · № რ-044521 · Verified on 16 Oct 2026 Off-label use A useful, generally safe parenteral replacement when true cobalamin deficiency is documented or strongly supported and injection is preferred for severity, adherence or clinical context. It should accompany cause-directed care and follow-up testing; oral supplementation is a credible less-invasive alternative for many stable dogs and cats. Regulatory and scientific credibility6.5/10 This exact Sopharma cyanocobalamin ampoule has sourced current registrations in Georgia and EU/EEA with identifiable strength, route and manufacturer, while current checks record no exact GB or US registration. Veterinary use is off-label and exact-product animal evidence is absent. Clinical efficacy7.5/10 Parenteral cobalamin reliably raises cobalamin and lowers methylmalonic acid in deficient dogs and cats, with feline clinical improvement reported and randomized canine evidence supporting biochemical normalization. It remains adjunctive to diagnosis and treatment of enteropathy, exocrine pancreatic insufficiency or another cause; oral cobalamin is often similarly effective, so injections are not inherently superior for every stable patient. Safety and tolerability8.0/10 Cyanocobalamin has a wide therapeutic margin and serious toxicity is uncommon. Relevant risks are injection pain, local inflammation, rare cobalt/cobalamin or excipient hypersensitivity including anaphylaxis, and potassium decline during brisk correction of severe deficiency; the exact human ampoule excipients and neonatal suitability require verification. Clinical practicality7.5/10 The sterile 500 mcg/ml single-use ampoule is straightforward for SC or IM replacement; a 250 mcg feline dose is 0.5 ml and published canine weight-band amounts fit practical volumes. Repeated injections and visits remain a burden compared with effective daily oral supplementation, and the ampoule remainder must be discarded. Full-course cost-effectiveness- Price was not assessed and is excluded from the overall score. Important safety and use flags Do not administer to a patient with known cobalt, cobalamin or product-excipient hypersensitivity. Parenteral vitamin B12 has rarely caused anaphylaxis; have observation and emergency treatment available, especially after a previous unexplained injection reaction. Confirm deficiency with an appropriate cobalamin assay and, when results or clinical response are equivocal, methylmalonic acid or other diagnostic context. Do not use cyanocobalamin as an empirical tonic, nonspecific appetite stimulant or substitute for investigating weight loss, anaemia, neuropathy or chronic gastrointestinal signs. Treat the cause of deficiency, including chronic enteropathy, ileal disease, exocrine pancreatic insufficiency, altered intestinal anatomy or an inadequate diet. Cobalamin can correct a deficiency marker but cannot by itself control inflammation, infection, pancreatic failure, neoplasia or malnutrition. Recheck clinical response and serum cobalamin after the replacement course and consider methylmalonic acid when functional deficiency remains uncertain. Draw planned baseline samples before supplementation and interpret very high post-treatment concentrations in light of timing rather than escalating automatically. During brisk correction of severe deficiency or megaloblastic anaemia, monitor potassium and the haematologic response; hypokalaemia and arrhythmia have been reported with intensive parenteral replacement. Investigate concurrent folate, iron or other deficiencies rather than assuming nonresponse means a higher B12 dose. Oral cobalamin normalized biochemical markers similarly to injections in randomized canine studies and has supportive feline evidence. Reassess whether repeated SC/IM visits, restraint and injection discomfort add value for a stable patient who can reliably receive an appropriate oral product. Verify the exact ampoule excipients before neonatal, very small, renal-impaired or repeated use; human cyanocobalamin products may contain benzyl alcohol or trace aluminum, and formulations are not interchangeable by appearance. Use only the labelled SC/IM routes and concentration. Protect the ampoule from light according to its insert, inspect the solution and container, use an accurate low-dead-space syringe and aseptic technique, rotate injection sites, and discard the unused remainder of a breached single-use ampoule rather than sharing it between patients. Assessment sources Cyanocobalamin injection market audit2026 DailyMed cyanocobalamin label2026 ACVIM canine CIE consensus2026 Canine oral versus injectable cobalamin2022 Canine cobalamin RCT2018 Feline injectable cobalamin2005 Feline vitamin B12 review2023 Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised. Cat SC or IM cyanocobalamin replacement for documented or strongly supported cobalamin deficiency when parenteral treatment is clinically preferred; not nonspecific appetite support, a tonic or automatic treatment of every gastrointestinal disorder 7.4/10 Good vetman assessment Vitamin B12 Sopharma 500 mcg/ml, 1 ml ampoule, solution for injection, human medicine Assessed clinical scopeCat · SC or IM cyanocobalamin replacement for documented or strongly supported cobalamin deficiency when parenteral treatment is clinically preferred; not nonspecific appetite support, a tonic or automatic treatment of every gastrointestinal disorder · SC,IM Care settingVeterinary clinic or a trained home-treatment plan after deficiency and cause assessment, with exact small-volume measurement, injection-site rotation, follow-up cobalamin or methylmalonic-acid testing and treatment of the underlying disease vetman score 7.4/10 Good Evidence confidence: Medium Georgia: Yes, human · № რ-044521 · Verified on 16 Oct 2026 Off-label use A useful, generally safe parenteral replacement when true cobalamin deficiency is documented or strongly supported and injection is preferred for severity, adherence or clinical context. It should accompany cause-directed care and follow-up testing; oral supplementation is a credible less-invasive alternative for many stable dogs and cats. Regulatory and scientific credibility6.5/10 This exact Sopharma cyanocobalamin ampoule has sourced current registrations in Georgia and EU/EEA with identifiable strength, route and manufacturer, while current checks record no exact GB or US registration. Veterinary use is off-label and exact-product animal evidence is absent. Clinical efficacy7.5/10 Parenteral cobalamin reliably raises cobalamin and lowers methylmalonic acid in deficient dogs and cats, with feline clinical improvement reported and randomized canine evidence supporting biochemical normalization. It remains adjunctive to diagnosis and treatment of enteropathy, exocrine pancreatic insufficiency or another cause; oral cobalamin is often similarly effective, so injections are not inherently superior for every stable patient. Safety and tolerability8.0/10 Cyanocobalamin has a wide therapeutic margin and serious toxicity is uncommon. Relevant risks are injection pain, local inflammation, rare cobalt/cobalamin or excipient hypersensitivity including anaphylaxis, and potassium decline during brisk correction of severe deficiency; the exact human ampoule excipients and neonatal suitability require verification. Clinical practicality7.5/10 The sterile 500 mcg/ml single-use ampoule is straightforward for SC or IM replacement; a 250 mcg feline dose is 0.5 ml and published canine weight-band amounts fit practical volumes. Repeated injections and visits remain a burden compared with effective daily oral supplementation, and the ampoule remainder must be discarded. Full-course cost-effectiveness- Price was not assessed and is excluded from the overall score. Important safety and use flags Do not administer to a patient with known cobalt, cobalamin or product-excipient hypersensitivity. Parenteral vitamin B12 has rarely caused anaphylaxis; have observation and emergency treatment available, especially after a previous unexplained injection reaction. Confirm deficiency with an appropriate cobalamin assay and, when results or clinical response are equivocal, methylmalonic acid or other diagnostic context. Do not use cyanocobalamin as an empirical tonic, nonspecific appetite stimulant or substitute for investigating weight loss, anaemia, neuropathy or chronic gastrointestinal signs. Treat the cause of deficiency, including chronic enteropathy, ileal disease, exocrine pancreatic insufficiency, altered intestinal anatomy or an inadequate diet. Cobalamin can correct a deficiency marker but cannot by itself control inflammation, infection, pancreatic failure, neoplasia or malnutrition. Recheck clinical response and serum cobalamin after the replacement course and consider methylmalonic acid when functional deficiency remains uncertain. Draw planned baseline samples before supplementation and interpret very high post-treatment concentrations in light of timing rather than escalating automatically. During brisk correction of severe deficiency or megaloblastic anaemia, monitor potassium and the haematologic response; hypokalaemia and arrhythmia have been reported with intensive parenteral replacement. Investigate concurrent folate, iron or other deficiencies rather than assuming nonresponse means a higher B12 dose. Oral cobalamin normalized biochemical markers similarly to injections in randomized canine studies and has supportive feline evidence. Reassess whether repeated SC/IM visits, restraint and injection discomfort add value for a stable patient who can reliably receive an appropriate oral product. Verify the exact ampoule excipients before neonatal, very small, renal-impaired or repeated use; human cyanocobalamin products may contain benzyl alcohol or trace aluminum, and formulations are not interchangeable by appearance. Use only the labelled SC/IM routes and concentration. Protect the ampoule from light according to its insert, inspect the solution and container, use an accurate low-dead-space syringe and aseptic technique, rotate injection sites, and discard the unused remainder of a breached single-use ampoule rather than sharing it between patients. Assessment sources Cyanocobalamin injection market audit2026 DailyMed cyanocobalamin label2026 ACVIM canine CIE consensus2026 Canine oral versus injectable cobalamin2022 Canine cobalamin RCT2018 Feline injectable cobalamin2005 Feline vitamin B12 review2023 Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised. Composition / strength Cyanocobalamin0.5 mg/ml Formulation Type Solution Administration route Subcutaneous, Intramuscular Manufacturer Sopharma · Bulgaria Registration Georgia Yes, human In force until 19 Dec 2030 Human (Ministry of Health, RAMA) In the register: ვიტამინი B12 სოფარმა 500 მკგ/მლ, 1 მლ ამპულა, საინექციო ხსნარი № რ-044521 mis.ge (Ministry of Health register incl. past registrations) Verified on: 16 Oct 2026 EU Yes, human EMA Article 57 database (all medicines authorised in the EU/EEA), 09.10.2026 Verified on: 16 Oct 2026 UK No MHRA Products (UK) Verified on: 16 Oct 2026 US No Drugs@FDA (openFDA) Verified on: 16 Oct 2026 Controlled in Georgia No Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n. matsne.gov.ge Verified on: 16 Oct 2026
1000 mcg/ml, Solution	No label dose in the reference yet	-	Georgia Yes, human In force until 19 Dec 2030 Human (Ministry of Health, RAMA) In the register: ვიტამინი B12 სოფარმა 1000 მკგ/მლ, 1 მლ ამპულა, საინექციო ხსნარი № რ-044522 mis.ge (Ministry of Health register incl. past registrations) Verified on: 16 Oct 2026
Details: pack, label wording, sources, registration Vitamin B12 Sopharma 1000 mcg/ml, Solution 1 ml ampoule, solution for injection, human medicine vetman assessment vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient. Dog SC or IM cyanocobalamin replacement for documented or strongly supported cobalamin deficiency when parenteral treatment is clinically preferred; not nonspecific appetite support, a tonic or automatic treatment of every gastrointestinal disorder 7.4/10 Good vetman assessment Vitamin B12 Sopharma 1000 mcg/ml, 1 ml ampoule, solution for injection, human medicine Assessed clinical scopeDog · SC or IM cyanocobalamin replacement for documented or strongly supported cobalamin deficiency when parenteral treatment is clinically preferred; not nonspecific appetite support, a tonic or automatic treatment of every gastrointestinal disorder · SC,IM Care settingVeterinary clinic or a trained home-treatment plan after deficiency and cause assessment, with exact small-volume measurement, injection-site rotation, follow-up cobalamin or methylmalonic-acid testing and treatment of the underlying disease vetman score 7.4/10 Good Evidence confidence: Medium Georgia: Yes, human · № რ-044522 · Verified on 16 Oct 2026 Off-label use A useful, generally safe parenteral replacement when true cobalamin deficiency is documented or strongly supported and injection is preferred for severity, adherence or clinical context. It should accompany cause-directed care and follow-up testing; oral supplementation is a credible less-invasive alternative for many stable dogs and cats. Regulatory and scientific credibility6.5/10 This exact Sopharma cyanocobalamin ampoule has sourced current registrations in Georgia and EU/EEA with identifiable strength, route and manufacturer, while current checks record no exact GB or US registration. Veterinary use is off-label and exact-product animal evidence is absent. Clinical efficacy7.5/10 Parenteral cobalamin reliably raises cobalamin and lowers methylmalonic acid in deficient dogs and cats, with feline clinical improvement reported and randomized canine evidence supporting biochemical normalization. It remains adjunctive to diagnosis and treatment of enteropathy, exocrine pancreatic insufficiency or another cause; oral cobalamin is often similarly effective, so injections are not inherently superior for every stable patient. Safety and tolerability8.0/10 Cyanocobalamin has a wide therapeutic margin and serious toxicity is uncommon. Relevant risks are injection pain, local inflammation, rare cobalt/cobalamin or excipient hypersensitivity including anaphylaxis, and potassium decline during brisk correction of severe deficiency; the exact human ampoule excipients and neonatal suitability require verification. Clinical practicality8.0/10 The sterile 1000 mcg/ml single-use ampoule supplies common feline and canine replacement amounts in a small SC or IM volume; a 250 mcg feline dose is 0.25 ml, so a precise low-dead-space syringe is required. Repeated injections and visits remain a burden compared with effective daily oral supplementation, and the ampoule remainder must be discarded. Full-course cost-effectiveness- Price was not assessed and is excluded from the overall score. Important safety and use flags Do not administer to a patient with known cobalt, cobalamin or product-excipient hypersensitivity. Parenteral vitamin B12 has rarely caused anaphylaxis; have observation and emergency treatment available, especially after a previous unexplained injection reaction. Confirm deficiency with an appropriate cobalamin assay and, when results or clinical response are equivocal, methylmalonic acid or other diagnostic context. Do not use cyanocobalamin as an empirical tonic, nonspecific appetite stimulant or substitute for investigating weight loss, anaemia, neuropathy or chronic gastrointestinal signs. Treat the cause of deficiency, including chronic enteropathy, ileal disease, exocrine pancreatic insufficiency, altered intestinal anatomy or an inadequate diet. Cobalamin can correct a deficiency marker but cannot by itself control inflammation, infection, pancreatic failure, neoplasia or malnutrition. Recheck clinical response and serum cobalamin after the replacement course and consider methylmalonic acid when functional deficiency remains uncertain. Draw planned baseline samples before supplementation and interpret very high post-treatment concentrations in light of timing rather than escalating automatically. During brisk correction of severe deficiency or megaloblastic anaemia, monitor potassium and the haematologic response; hypokalaemia and arrhythmia have been reported with intensive parenteral replacement. Investigate concurrent folate, iron or other deficiencies rather than assuming nonresponse means a higher B12 dose. Oral cobalamin normalized biochemical markers similarly to injections in randomized canine studies and has supportive feline evidence. Reassess whether repeated SC/IM visits, restraint and injection discomfort add value for a stable patient who can reliably receive an appropriate oral product. Verify the exact ampoule excipients before neonatal, very small, renal-impaired or repeated use; human cyanocobalamin products may contain benzyl alcohol or trace aluminum, and formulations are not interchangeable by appearance. Use only the labelled SC/IM routes and concentration. Protect the ampoule from light according to its insert, inspect the solution and container, use an accurate low-dead-space syringe and aseptic technique, rotate injection sites, and discard the unused remainder of a breached single-use ampoule rather than sharing it between patients. Assessment sources Cyanocobalamin injection market audit2026 DailyMed cyanocobalamin label2026 ACVIM canine CIE consensus2026 Canine oral versus injectable cobalamin2022 Canine cobalamin RCT2018 Feline injectable cobalamin2005 Feline vitamin B12 review2023 Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised. Cat SC or IM cyanocobalamin replacement for documented or strongly supported cobalamin deficiency when parenteral treatment is clinically preferred; not nonspecific appetite support, a tonic or automatic treatment of every gastrointestinal disorder 7.4/10 Good vetman assessment Vitamin B12 Sopharma 1000 mcg/ml, 1 ml ampoule, solution for injection, human medicine Assessed clinical scopeCat · SC or IM cyanocobalamin replacement for documented or strongly supported cobalamin deficiency when parenteral treatment is clinically preferred; not nonspecific appetite support, a tonic or automatic treatment of every gastrointestinal disorder · SC,IM Care settingVeterinary clinic or a trained home-treatment plan after deficiency and cause assessment, with exact small-volume measurement, injection-site rotation, follow-up cobalamin or methylmalonic-acid testing and treatment of the underlying disease vetman score 7.4/10 Good Evidence confidence: Medium Georgia: Yes, human · № რ-044522 · Verified on 16 Oct 2026 Off-label use A useful, generally safe parenteral replacement when true cobalamin deficiency is documented or strongly supported and injection is preferred for severity, adherence or clinical context. It should accompany cause-directed care and follow-up testing; oral supplementation is a credible less-invasive alternative for many stable dogs and cats. Regulatory and scientific credibility6.5/10 This exact Sopharma cyanocobalamin ampoule has sourced current registrations in Georgia and EU/EEA with identifiable strength, route and manufacturer, while current checks record no exact GB or US registration. Veterinary use is off-label and exact-product animal evidence is absent. Clinical efficacy7.5/10 Parenteral cobalamin reliably raises cobalamin and lowers methylmalonic acid in deficient dogs and cats, with feline clinical improvement reported and randomized canine evidence supporting biochemical normalization. It remains adjunctive to diagnosis and treatment of enteropathy, exocrine pancreatic insufficiency or another cause; oral cobalamin is often similarly effective, so injections are not inherently superior for every stable patient. Safety and tolerability8.0/10 Cyanocobalamin has a wide therapeutic margin and serious toxicity is uncommon. Relevant risks are injection pain, local inflammation, rare cobalt/cobalamin or excipient hypersensitivity including anaphylaxis, and potassium decline during brisk correction of severe deficiency; the exact human ampoule excipients and neonatal suitability require verification. Clinical practicality8.0/10 The sterile 1000 mcg/ml single-use ampoule supplies common feline and canine replacement amounts in a small SC or IM volume; a 250 mcg feline dose is 0.25 ml, so a precise low-dead-space syringe is required. Repeated injections and visits remain a burden compared with effective daily oral supplementation, and the ampoule remainder must be discarded. Full-course cost-effectiveness- Price was not assessed and is excluded from the overall score. Important safety and use flags Do not administer to a patient with known cobalt, cobalamin or product-excipient hypersensitivity. Parenteral vitamin B12 has rarely caused anaphylaxis; have observation and emergency treatment available, especially after a previous unexplained injection reaction. Confirm deficiency with an appropriate cobalamin assay and, when results or clinical response are equivocal, methylmalonic acid or other diagnostic context. Do not use cyanocobalamin as an empirical tonic, nonspecific appetite stimulant or substitute for investigating weight loss, anaemia, neuropathy or chronic gastrointestinal signs. Treat the cause of deficiency, including chronic enteropathy, ileal disease, exocrine pancreatic insufficiency, altered intestinal anatomy or an inadequate diet. Cobalamin can correct a deficiency marker but cannot by itself control inflammation, infection, pancreatic failure, neoplasia or malnutrition. Recheck clinical response and serum cobalamin after the replacement course and consider methylmalonic acid when functional deficiency remains uncertain. Draw planned baseline samples before supplementation and interpret very high post-treatment concentrations in light of timing rather than escalating automatically. During brisk correction of severe deficiency or megaloblastic anaemia, monitor potassium and the haematologic response; hypokalaemia and arrhythmia have been reported with intensive parenteral replacement. Investigate concurrent folate, iron or other deficiencies rather than assuming nonresponse means a higher B12 dose. Oral cobalamin normalized biochemical markers similarly to injections in randomized canine studies and has supportive feline evidence. Reassess whether repeated SC/IM visits, restraint and injection discomfort add value for a stable patient who can reliably receive an appropriate oral product. Verify the exact ampoule excipients before neonatal, very small, renal-impaired or repeated use; human cyanocobalamin products may contain benzyl alcohol or trace aluminum, and formulations are not interchangeable by appearance. Use only the labelled SC/IM routes and concentration. Protect the ampoule from light according to its insert, inspect the solution and container, use an accurate low-dead-space syringe and aseptic technique, rotate injection sites, and discard the unused remainder of a breached single-use ampoule rather than sharing it between patients. Assessment sources Cyanocobalamin injection market audit2026 DailyMed cyanocobalamin label2026 ACVIM canine CIE consensus2026 Canine oral versus injectable cobalamin2022 Canine cobalamin RCT2018 Feline injectable cobalamin2005 Feline vitamin B12 review2023 Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised. Composition / strength Cyanocobalamin1 mg/ml Formulation Type Solution Administration route Subcutaneous, Intramuscular Manufacturer Sopharma · Bulgaria Registration Georgia Yes, human In force until 19 Dec 2030 Human (Ministry of Health, RAMA) In the register: ვიტამინი B12 სოფარმა 1000 მკგ/მლ, 1 მლ ამპულა, საინექციო ხსნარი № რ-044522 mis.ge (Ministry of Health register incl. past registrations) Verified on: 16 Oct 2026 EU Yes, human EMA Article 57 database (all medicines authorised in the EU/EEA), 09.10.2026 Verified on: 16 Oct 2026 UK No MHRA Products (UK) Verified on: 16 Oct 2026 US No Drugs@FDA (openFDA) Verified on: 16 Oct 2026 Controlled in Georgia No Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n. matsne.gov.ge Verified on: 16 Oct 2026

Active substance doses, with sources

Each dose comes with its source. Check the label of the product you use.

Active substance Cyanocobalamin

Dose calculatorCalculates the active-substance amount; it is not a prescription.

PatientSpecies and weight will be filled in automatically in other calculators.

Species Weight (kg)

Indication

Selected dose

Product presentation

Dose	Species	Indication	Route	Frequency	Source
25 mcg/kg off-label	Dog	Maintenance	By mouth	once daily	MSD Vet Manual 2025 Reference book A veterinary reference written and reviewed by specialists, summarising accepted practice. The product label gives the authorised dose. Exocrine Pancreatic Insufficiency in Dogs and Cats MSD/Merck Veterinary Manual, 2025 Open the source ↗
25 mcg/kg off-label	Dog	Maintenance	Subcutaneous	once weekly	MSD Vet Manual 2025 Reference book A veterinary reference written and reviewed by specialists, summarising accepted practice. The product label gives the authorised dose. Exocrine Pancreatic Insufficiency in Dogs and Cats MSD/Merck Veterinary Manual, 2025 Open the source ↗
0.25 mg per animal off-label	Cat	Maintenance	By mouth	once daily	MSD Vet Manual 2025 Reference book A veterinary reference written and reviewed by specialists, summarising accepted practice. The product label gives the authorised dose. Exocrine Pancreatic Insufficiency in Dogs and Cats MSD/Merck Veterinary Manual, 2025 Open the source ↗
0.25 mg per animal off-label	Cat	Maintenance	Subcutaneous	once weekly	MSD Vet Manual 2025 Reference book A veterinary reference written and reviewed by specialists, summarising accepted practice. The product label gives the authorised dose. Exocrine Pancreatic Insufficiency in Dogs and Cats MSD/Merck Veterinary Manual, 2025 Open the source ↗

Known Contraindications

Warning
Tumours: according to the product label, vitamin B12 may stimulate the growth of malignant tumours, so it should not be given to patients with a tumour.

Sources: Product label

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 16 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Vitamin B12 Sopharma

Forms and doses2 of 2 in force in Georgia